AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$OBIO

Taylor Andrew Lawrence purchased $5K of OBIO

Taylor Andrew Lawrence (Chief Financial Officer) purchased 1,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 on 2026-11-09.

Original reporting
SEC EDGAR · Taylor Andrew Lawrence
Published Nov 9, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
high confidence
Mentioned
$OBIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The filing provides a primary source of insider activity but the small transaction size limits market impact.

02

Market read

Insider purchase is a routine disclosure with minimal trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed may influence future insider activity.

Relevance 4/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider purchase by the CFO of Orchestra BioMed Holdings.

Company-level read

Ticker impact

$OBIONeutralHigh confidence
Context

CFO Taylor Andrew Lawrence purchased 1,000 shares of OBIO at $5 each, raising his stake to 590,989 shares.

Expected impact

minor positive pressure, unlikely to move the stock

Evidence & confidence

Form 4 filing is primary source; however, the transaction amount is trivial for a public company.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    Orchestra BioMed Holdings, Inc.

    Biopharmaceutical company listed on NASDAQ under ticker OBIO.

  • person
    Taylor Andrew Lawrence

    Chief Financial Officer of OBIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OBIO insider trading history →

Related articles

$OBIOMed

H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Orchestra BioMed (OBIO) after its hypertension trial completed enrollment. The stock trades at $5.95, with a 119.56% return over the past year. The BACKBEAT trial, conducted with Medtronic, aims to treat uncontrolled hypertension in pacemaker patients. Orchestra plans to submit results for regulatory review in 2027. BTIG also upgraded OBIO to Buy with a $10 target.

investing.com